Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
收藏官方服务：
资源简介：
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
应用场景：
创建时间：
2022-05-11
相关数据集
DataSheet_1_Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.pdf
Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in parti
NIAID Data Ecosystem20
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
NCATS Open Data2022-03-11 更新10
Table_1_Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial.docx
BackgroundCoronaVac has been authorized worldwide for preventing coronavirus disease 2019. Information on the safety, immunogenicity and consistency of different lots and workshops of CoronaVac is pre
NIAID Data Ecosystem00
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
NCATS Open Data2021-11-12 更新10
Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children
Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children
NCATS Open Data2023-07-21 更新10
